USP10 Activators

USP10 activators consist of a diverse range of compounds that indirectly influence the activity of USP10 through their effects on cellular proteostasis and signaling pathways. These activators primarily operate by modulating the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathways, which are intricately linked with the function of deubiquitinating enzymes like USP10. Compounds such as MG132, Bortezomib, Epoxomicin, and Lactacystin are proteasome inhibitors. They lead to an accumulation of ubiquitinated proteins within the cell, thereby potentially increasing the functional demand on deubiquitinating enzymes, including USP10. This accumulation can indirectly enhance the activity of USP10 as it may be required to process the increased load of ubiquitinated substrates.

In addition, other compounds like PYR-41, which inhibits ubiquitin-activating enzymes, and IU1, an inhibitor of USP14, can alter the dynamics of ubiquitination and deubiquitination within the cell. These alterations can create a cellular environment where the role of USP10 in maintaining protein stability and regulating protein turnover becomes more pronounced. Moreover, agents like Chloroquine and 3-Methyladenine (3-MA) that affect lysosomal function and autophagy, respectively, also contribute to the modulation of protein degradation pathways